The Mastermind Agenda is out. Educational mobility promotes longevity. Chat about Lp(a) lowering therapies.

Your weekly sneak peek into the world of Longevity Docs.

Apr 07, 2024

Hi Longevity Docs!

Our mission at Longevity Docs is to democratize longevity medicine. In this newsletter, I'll share a behind-the-scenes look at our growing community and our effort to empower longevity physicians globally.

Mastermind Event: excited to share our agenda with you all.

In the Chat: Lp(a) lowering therapies need to be affordable and demonstrate positive outcome data.

Publications: a study show that educational mobility may slow the pace of biological aging and promote longevity.

Community: in this week's community poll, doctors are showing a strong interest in workshop sessions, experience sharing meetups, and networking gatherings during the masterclass.

Yes I know I’m mentioning the Mastermind again. Don’t miss it: NYC, April 27 ;)

Stay Young!

Dr. David Luu

Book your ticket

🗞️ Longevity Docs Updates

The Mastermind Agenda is out:

9:00 AM - 9:30 AM: Welcome address: Introducing the Longevity Docs Network

Host: Dr. Jessica Shepherd
Chair: Pr. Zahi Fayad
Founder: Dr. David Luu

9:30 AM - 10:30 AM: Crafting a Comprehensive Longevity Assessment: From Epigenetics and Microbiome Analysis to Functional Tests and Digital Biomarkers

Moderated by Dr. Poonam Desai
Dr. Elizabeth Yurth
Dr. Florence Comite
Dr. Elena Ivanina
Ryan Smith

10:30 AM - 11:30 AM: Preventing Age-Related Conditions: Advances in Cardiac, Brain, Sexual, Hormonal, and Immunological Health Management

Moderated by Jessica Shepherd
Dr. Amy Killen
Dr. Giovanni Campanile
Dr. Robin Forman Rose
Dr. Roxanna Namavar
Nikolina Lauc

11:30 AM - 12:30 PM: Challenges and Insights in Building a Longevity-Focused Practice: Comparing Brick-and-Mortar Versus Virtual Models

Moderated by Dr. David Luu
Dr. Tamsin Lewis
Dr. Anant Vinjamoori
Dr. Mohammed Enayat
Dr. Sajad Zalzala

12:30 PM - 1:30 PM: Lunch Roundtables: Discovering the Latest Innovations

1:30 PM - 2:30 PM: Decoding the Longevity Shift - Celebrity Phenomenon or Societal Movement?

Moderated by Dr. David Luu
Dr. Frank Lipman

2:30 PM - 3:30 PM: Democratizing Advanced Longevity Practices and Technology Through Academic and Research Collaboration

Moderated by Pr. Zahi Fayad, PhD
Dr. James Min
Dr. Louis DePalo
Jan Krumsiek, Ph.D

4:00 PM - 5:00 PM: Promising Longevity Therapies: Navigating the Crossroads of Regulatory Boundaries and Scientific Breakthroughs

Moderated by Dr. Elizabeth Yurth
Dr. David Barzilai
Dr. Neil Paulvin
Dr. Jonathann Kuo
Dr. Steven Murphy
Dr. James Peyer

5:00 PM - 5:15 PM: Final Reflections on Democratizing Longevity Medicine: Pathways to Inclusive Progress

Book Your Ticket - Limited to 50

💬 Community Spotlight

Buzz In the Chat: Balancing Outcomes and Costs in Lp(a) Lowering Therapies

If you miss it, our Docs discussed the promise of new Lp(a) lowering drugs amidst concerns over their cost and the pressing need for outcome data.

Doc 1: Several other drugs in the pipeline for lowering Lp(a). Can’t wait until they’re available
Doc 2: As usual , we need outcome data- keep our fingers crossed
Doc 3: What's the bet on the monthly costs??
Doc 4: $3,000
Doc 5: The NAFLD med with marginal benefit is $4k.
Doc 4: Yeah...prob right. Ok...Ill change to 5000
Doc 5: Bet even more. x30years. $1.8m per person.
Doc 6: I've seen a ton of patients reverse NAFLD with the GLP agonists. Full reversal in one patient in just 9 months
Doc 1: My guess is $20k a year. Twice a year injection. As someone with elevated Lp(a) I’m interested in outcomes data but understanding the pathophysiology of Lp(a) and its association with atherosclerosis I will plan to take it when it’s clinically available.
Doc 7: I wonder what the criteria for treatment will be for Lp(a) lowering therapy?Lots of people we see with elevated Lp(a). Some that genuinely have premature CAD and lots who dont.
Doc 8: I think about the stroke implications with Lp(a) paired with A blood type powerful risk indicators for early onset stroke.
Doc 9: Hopefully after this Phase II trial of Zelasiran an outcomes trial will show reduced MI, CVA and AS risk. Remember that Niacin in some studies have shown up to a 40% reduction of Lp(a), however, no benefit in outcomes- so essentially useless
Doc 10: Yes. The Lp(a) saga is far from cut and dry, just like niacin
Doc 1: I understand in the primary prevention and secondary prevention trials with niacin there was no mortality benefit but to my knowledge there hasn’t been an outcomes study with niacin for those persons that have elevated Lp(a) as the primary lipid abnormality.

🩺 Publications

Urolithins: The Colon Microbiota Metabolites as Endocrine Modulators: Prospects and Perspectives

In this review, we unveil the possibility of urolithins as a potent SERM, which we are currently investigating, in the hormone dependent tissues.

Frontiers in Nutrition - Recommended by Dr. Felice Gersh

Educational Mobility, Pace of Aging, and Lifespan Among Participants in the Framingham Heart Study

This study suggests that interventions to promote educational attainment may slow the pace of biological aging and promote longevity.

JAMA - Recommended by Dr. David Luu

Impact of 8 lifestyle factors on mortality and life expectancy among United States veterans: The Million Veteran Program

This study aimed to estimate mortality risk and longevity associated with individual lifestyle factors and comprehensive lifestyle therapy.

The American Journal of Clinical Nutrition - Recommended by Dr. Steven Murphy

Effect of Iron Deficiency Anemia on Blood Glucose and Insulin Resistance in Women with Type II Diabetes

IDA treatment in patients with T2DM can significantly reduce the BG and IR levels. To better control BG, checking iron status and its correction may provide better clinical outcomes in these patients.

Rev Recent Clin Trials - Recommended by Dr. Guenole Addor

🎓 Masterclass

Longevity Therapeutics with Dr. Neil Paulvin

Join us for an exclusive opportunity to learn directly from Dr. Neil Paulvin. Dive deep into the world of longevity therapeutics and discover the latest advancements with one of the field's leading experts. Don't miss this transformative learning experience.

Members-only - Apply here

👩‍⚕️ Job Board

Career Opportunities Await in the Field of Longevity

Chief Medical Officer - functional medicine & longevity clinic - Dubai - Full-time
CEO - Longevity Clinic - London - Full-time
Longevity Physician - Virtual Clinic - US, 50 states - Part-time
Longevity Physicians - Longevity clinic - New York City - Part-time

🌐 News

Zerlasiran siRNA Drug Lowers Lp(a) by 90% in Phase 2 Results

Study documents safety, improvements from stem cell therapy after spinal cord injury

🗓️ Events & conferences

👉 Join Waitlist: Longevity Docs Mastermind: New York City - April 27

Book your Ticket - Limited to 50

HealthCon: NYC - April 13
Rejuvenation Startup Summit: Berlin - May 10-11
Global Wellness Real Estate & Communities Symposium: NYC - May 14
NextMed Health: San Diego - Dec 10-13

About Longevity Docs

Longevity Docs is a highly-vetted membership network dedicated to physicians pioneering precision and evidence-based practices in longevity medicine.

Learn More